{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=14", "query": { "condition": "High-Risk", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 7258, "total_pages": 726, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T19:25:47.500Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01208662", "title": "Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Paul Richardson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 729, "start_date": "2010-09", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01208662" }, { "nct_id": "NCT07022470", "title": "Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancers" ], "interventions": [ { "name": "3-Fraction HDR Brachytherapy", "type": "RADIATION" }, { "name": "4-Fraction HDR Brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2025-06-03", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07022470" }, { "nct_id": "NCT03261323", "title": "Breast Reconstruction Following Breast Cancer in Very High Risk Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Immediate Breast Reconstruction", "type": "PROCEDURE" }, { "name": "Delayed Breast Reconstruction", "type": "PROCEDURE" }, { "name": "Breast-Q questionnaire", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2019-05-31", "completion_date": "2022-07", "has_results": false, "last_update_posted_date": "2022-05-20", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03261323" }, { "nct_id": "NCT04024670", "title": "The Impact of Arts-Based Interventions on Patient Hospital Experience", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "High Risk Pregnancy", "Bone Marrow" ], "interventions": [ { "name": "Arts Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2019-01-01", "completion_date": "2023-08-01", "has_results": false, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04024670" }, { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT04873362", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1188, "start_date": "2021-05-04", "completion_date": "2034-10-02", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Buena", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04873362" }, { "nct_id": "NCT06636162", "title": "Window of Opportunity Study of DSP-0390 in Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioma, Malignant", "IDH Mutation" ], "interventions": [ { "name": "DSP-0390", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-04-03", "completion_date": "2027-05-17", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06636162" }, { "nct_id": "NCT02115295", "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Blasts 10 Percent or More of Bone Marrow Nucleated Cells", "Blasts 10 Percent or More of Peripheral Blood White Cells", "de Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Midostaurin", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 508, "start_date": "2014-05-19", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115295" }, { "nct_id": "NCT00562328", "title": "Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 33, "start_date": "2008-01", "completion_date": "2014-12-18", "has_results": true, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562328" }, { "nct_id": "NCT00405834", "title": "A Pilot Study of the Envision® Surface", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pressure Ulcers" ], "interventions": [ { "name": "Envision® Patient Support System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Hill-Rom", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2007-06", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2008-07-04", "last_synced_at": "2026-11-05T19:25:47.500Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405834" } ] }